These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

129 related items for PubMed ID: 24939215

  • 1. Tailoring the GVHD prophylaxis regimen according to transplantation associated toxicities-Substituting the 3rd dose of methotrexate to mycophenolate mofetil.
    Ram R, Herscovici C, Dahan D, Israeli M, Dreyer J, Peck A, Shpilberg O, Yeshurun M.
    Leuk Res; 2014 Aug; 38(8):913-7. PubMed ID: 24939215
    [Abstract] [Full Text] [Related]

  • 2. MTX or mycophenolate mofetil with CsA as GVHD prophylaxis after reduced-intensity conditioning PBSCT from HLA-identical siblings.
    Piñana JL, Valcárcel D, Fernández-Avilés F, Martino R, Rovira M, Barba P, Martínez C, Brunet S, Sureda A, Carreras E, Sierra J.
    Bone Marrow Transplant; 2010 Sep; 45(9):1449-56. PubMed ID: 20140024
    [Abstract] [Full Text] [Related]

  • 3. Enteric-coated mycophenolate sodium containing GvHD prophylaxis reduces GvHD rate after allogeneic HSCT.
    Weber T, Niestadtkötter J, Wienke A, Müller-Tidow C, Müller LP.
    Eur J Haematol; 2016 Sep; 97(3):232-8. PubMed ID: 26613546
    [Abstract] [Full Text] [Related]

  • 4. Cyclosporine A and mycophenolate mofetil vs cyclosporine A and methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblings.
    Neumann F, Graef T, Tapprich C, Vaupel M, Steidl U, Germing U, Fenk R, Hinke A, Haas R, Kobbe G.
    Bone Marrow Transplant; 2005 Jun; 35(11):1089-93. PubMed ID: 15821769
    [Abstract] [Full Text] [Related]

  • 5. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation.
    Bolwell B, Sobecks R, Pohlman B, Andresen S, Rybicki L, Kuczkowski E, Kalaycio M.
    Bone Marrow Transplant; 2004 Oct; 34(7):621-5. PubMed ID: 15300236
    [Abstract] [Full Text] [Related]

  • 6. A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation.
    Nash RA, Johnston L, Parker P, McCune JS, Storer B, Slattery JT, Furlong T, Anasetti C, Appelbaum FR, Lloid ME, Deeg HJ, Kiem HP, Martin PJ, Schubert MM, Witherspoon RP, Forman SJ, Blume KG, Storb R.
    Biol Blood Marrow Transplant; 2005 Jul; 11(7):495-505. PubMed ID: 15983549
    [Abstract] [Full Text] [Related]

  • 7. Graft-versus-host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality.
    Sabry W, Le Blanc R, Labbé AC, Sauvageau G, Couban S, Kiss T, Busque L, Cohen S, Lachance S, Roy DC, Roy J.
    Biol Blood Marrow Transplant; 2009 Aug; 15(8):919-29. PubMed ID: 19589481
    [Abstract] [Full Text] [Related]

  • 8. Combination of low-dose mycophenolate mofetil with cyclosporine and methotrexate as GVHD prophylaxis in unrelated donor allogeneic stem cell transplantation.
    Zhu X, Lai X, Luo Y, Shi J, Tan Y, Zheng W, He J, Xie W, Li L, Zhang J, Ye X, Lin M, Cai Z, Huang H.
    Leuk Res; 2013 Sep; 37(9):1046-51. PubMed ID: 23849987
    [Abstract] [Full Text] [Related]

  • 9. [Quadruple therapy with CsA, MTX, MMF and ATG for preventing graft-versus-host disease in unrelated donor hematopoietic stem cell transplantation].
    Liu QF, Sun J, Zhang Y, Xu D, Liu XL, Xu B, Meng FY, Zhou SY.
    Di Yi Jun Yi Da Xue Xue Bao; 2003 Nov; 23(11):1143-5. PubMed ID: 14625172
    [Abstract] [Full Text] [Related]

  • 10. [Study on graft-versus-host disease in the allogeneic peripheral blood stem cell transplantation for the treatment of leukemia].
    Zhang WP, Wang JM, Ju XP, Song XM, Tong SP, Li HM.
    Zhonghua Xue Ye Xue Za Zhi; 2003 Mar; 24(3):129-33. PubMed ID: 12697123
    [Abstract] [Full Text] [Related]

  • 11. Decreased risk of acute gastrointestinal toxicity when substituting methotrexate with mycophenolate mofetil in the prevention of graft-versus-host disease in stem cell transplantation following myeloablative conditioning regimens.
    Pohlreich D, Vitek A, Maalouf J, Cetkovsky P.
    Bone Marrow Transplant; 2006 Jan; 37(2):235-6; author reply 236-7. PubMed ID: 16284607
    [No Abstract] [Full Text] [Related]

  • 12. [Combination of mycophenolate mofetil with cyclosporine A and methotrexate for the prophylaxes of acute graft versus host disease in allogeneic peripheral stem cell transplantation].
    Wang J, Song X, Zhang W, Tong S, Hou J, Chen L, Lou J, Li H, Ding X, Min B.
    Zhonghua Yi Xue Za Zhi; 2002 Apr 25; 82(8):507-10. PubMed ID: 12133492
    [Abstract] [Full Text] [Related]

  • 13. Substitution of methotrexate with corticosteroid for acute graft-versus-host disease prevention in transplanted patients who develop methotrexate toxicity.
    Kim SY, Kim AR, Yoon SY, Cho YH, Lee MH.
    Ann Hematol; 2016 Feb 25; 95(3):483-91. PubMed ID: 26658911
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Long-term follow-up of a prospective randomized trial comparing CYA and MTX with CYA and mycophenolate mofetil for GVHD prophylaxis in myeloablative sibling donor hematopoietic cell transplantation.
    Hamilton BK, Bolwell B, Kalaycio M, Rybicki L, Hanna R, Sobecks R, Pohlman B, Andresen S, Dean R, Duong H, Hill B, Copelan E.
    Bone Marrow Transplant; 2013 Nov 25; 48(12):1578-80. PubMed ID: 23749105
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203).
    Bolaños-Meade J, Reshef R, Fraser R, Fei M, Abhyankar S, Al-Kadhimi Z, Alousi AM, Antin JH, Arai S, Bickett K, Chen YB, Damon LE, Efebera YA, Geller NL, Giralt SA, Hari P, Holtan SG, Horowitz MM, Jacobsohn DA, Jones RJ, Liesveld JL, Logan BR, MacMillan ML, Mielcarek M, Noel P, Pidala J, Porter DL, Pusic I, Sobecks R, Solomon SR, Weisdorf DJ, Wu J, Pasquini MC, Koreth J.
    Lancet Haematol; 2019 Mar 25; 6(3):e132-e143. PubMed ID: 30824040
    [Abstract] [Full Text] [Related]

  • 18. [Mycophenolate mofetil in treatment of graft-versus-host disease after allogeneic hematopoietic cell transplantation: analysis of 44 cases].
    Chen H, Liu KY, Liu DH, Xu LP, Han W, Chen YH, Huang XJ.
    Zhonghua Yi Xue Za Zhi; 2008 Aug 05; 88(30):2127-30. PubMed ID: 19080474
    [Abstract] [Full Text] [Related]

  • 19. A pilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant recipients.
    Osunkwo I, Bessmertny O, Harrison L, Cheung YK, Van de Ven C, del Toro G, Garvin J, George D, Bradley MB, Wolownik K, Wischhover C, Levy J, Skerrett D, Cairo MS.
    Biol Blood Marrow Transplant; 2004 Apr 05; 10(4):246-58. PubMed ID: 15077223
    [Abstract] [Full Text] [Related]

  • 20. High incidence of severe acute graft-versus-host disease with tacrolimus and mycophenolate mofetil in a large cohort of related and unrelated allogeneic transplantation patients.
    Al-Kadhimi Z, Gul Z, Chen W, Smith D, Abidi M, Deol A, Ayash L, Lum L, Waller EK, Ratanatharathorn V, Uberti J.
    Biol Blood Marrow Transplant; 2014 Jul 05; 20(7):979-85. PubMed ID: 24709007
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.